Previous 10 | Next 10 |
2024-02-12 09:33:50 ET CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.5...
2024-02-12 08:53:47 ET Gilead Sciences ( NASDAQ: GILD ) has agreed to acquire CymaBay Therapeutics ( NASDAQ: CBAY ) for a total equity value of $4.3B.... Read the full article on Seeking Alpha For further details see: Gilead to acquire CymaBay for $32.50/...
-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC --...
2024-02-11 08:19:38 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-02-10 03:58:57 ET Summary Gilead Sciences reported its Q4 2023 results, which paint a picture of a stagnant company. Zooming in more closely, Gilead's different product categories show highly differentiating growth rates. While Gilead's HIV business is mostly flat with mo...
– Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead ...
2024-02-08 14:37:16 ET More on Kyverna Therapeutics, Inc. Kyverna Therapeutics Starts $100 Million IPO Effort Kyverna Therapeutics prices initial $319M offering at $22 per share Kyverna Therapeutics upsizes proposed IPO to $297M Financial information for Kyve...
2024-02-07 15:48:54 ET Shares of Gilead Sciences (NASDAQ: GILD) are down 3.7% as of 3:30 p.m. ET Wednesday after the biopharmaceuticals giant announced mixed quarterly results relative to Wall Street's expectations. Gilead's fourth-quarter 2023 revenue declined 3.7% year over ye...
2024-02-07 15:17:16 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead Sciences: The Sky Is Not Falling Gilead stock dips after hours amid lacklu...
2024-02-07 13:23:24 ET More on S&P 500 Index: A Technical View Of Potential Downside For The Market Sterling Moves Back Into Previous Trading Range, But Will It Hold? The Warning Signs In The Stock Market Are Clear And Present (Technical Analysis) Histori...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...